The science of discovery comes with ethical challenges in human clinical trials By Richard Jefferys Over the past several years, there has been a welcome invigoration of the research effort to cure HIV infection. The mainstream media has picked up…
By Tim Horn Though the number of new HIV infections in the United States is down from its peak in the 1980s, incidence has refused to budge below its decade-long average: roughly 50,000 American residents are infected with the virus…
ACT UP/NY demands Department of Health accountability at the epicenter of the U.S. epidemic and commits to reinvigorate the national prevention agenda By Jim Eigo and James Krellenstein, ACT UP/NY The authors, James Krellenstein (left) and Jim Eigo, at an…
A coalition of community groups push to end AIDS at the epicenter of the U.S. epidemic Beginning in January 2013, a coalition of New York HIV/AIDS leaders came together to begin a series of discussions to reenvision the state’s HIV/AIDS…
Getting more HIV-positive people linked to and retained in care requires innovation and research By Tim Horn Viral-load suppression remains the holy grail of HIV care. Its associations with AIDS-free survival and a profound reduction in transmission risk are well…
President Obama orders multiagency cooperation to achieve National HIV/AIDS Strategy goals, but without required funding commitment By Scott Morgan If the United States is to effectively move toward the 2015 goals outlined in the National HIV/AIDS Strategy (NHAS) through the…
By Mark Harrington In death one can’t be vocal or witness time and motion and physical events with breath, one can’t make change. Abstract ideas of energy dispersing, some ethical ocean crawls through a funnel of stars, outlines of the…
The Domestic Issue: We're at a stalemate. This issue of TAGline underscores TAG’s commitment to ending AIDS in the United States and realizing the goals of the National HIV/AIDS Strategy.
TAG and 134 other organizations sent this letter to underscore the need for a swift response from UNITAID to hepatitis C virus (HCV) coinfection; delays will cost lives and impede scale-up when more effective and tolerable therapies are available.
On September 19th, 2013, the National Institute of Allergy and Infectious Diseases (NIAID) sponsored a daylong mini-summit to discuss the safety of adenovirus vaccine vectors in populations at risk for HIV infection.